[Multifactorial treatment of atherosclerosis].
Cardiovascular diseases, the clinical paradigm of atherosclerosis, are the primary cause of mortality in developed countries. The origin of the atheromatous lesion is multifactorial, as it is the therapeutic approach to its prevention and clinical complications. The initial symptoms of ischemia in a vascular bed are usually evident when the atherosclerotic process is very advanced, being indicative of a diffuse disease and of an elevated future risk for ischemic events in other vascular territories. We perform this review in this clinical scenario, highlighting the preventive and therapeutic aspects of demonstrated clinical efficacy, with no detail of those treatments with benefit insufficiently proven.
Mangas Rojas
Alipio
A
Servicio de Medicina Interna, Hospital Universitario Puerta del Mar, Cádiz, España.
Gómez Rodríguez
Francisco
F
D000787:Angina Pectoris / Q000188:drug therapy; D000925:Anticoagulants / Q000627:therapeutic use; D050197:Atherosclerosis / Q000188:drug therapy / Q000517:prevention & control / Q000628:therapy*; D002545:Brain Ischemia / Q000188:drug therapy / Q000517:prevention & control / Q000601:surgery; D002317:Cardiovascular Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D006333:Heart Failure / Q000188:drug therapy; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D009203:Myocardial Infarction / Q000188:drug therapy; D017202:Myocardial Ischemia / Q000188:drug therapy / Q000517:prevention & control; D016491:Peripheral Vascular Diseases / Q000188:drug therapy; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D012307:Risk Factors
D000925:Anticoagulants; D002317:Cardiovascular Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D010975:Platelet Aggregation Inhibitors